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Aggressive fibromatosis is a locally invasive soft tissue lesion
composed of a clonal proliferation of spindle (fibroblast-like) cells
(Alman et al, 1997a). It harbours somatic mutations in either the
adenomatous polyposis coli (APC) gene or the b-catenin gene,
resulting in b-catenin protein stabilization (Alman et al, 1997b; Li 
et al, 1998; Tejpar et al, 1999). b-catenin is located in the nucleus
in aggressive fibromatosis, suggesting a role in nuclear transcrip-
tion (Tejpar et al, 1999). 
b-catenin is a key signalling molecule in the Wnt signalling
pathway. Activation of the pathway results in b-catenin protein
stabilization. When stabilized, it binds to members of the t-cell
factor-lymphoid enhancer factor (tcf-lef) family, forming a tran-
scriptional activating complex. Mutations in b-catenin, removing
amino terminal phosphorylation sites, or mutations in the
members of a multi-protein complex that aids in b-catenin degra-
dation, such as APC, also cause b-catenin stabilization (Miller 
et al, 1999). 
Tcf/lef family members are architectural transcription factors,
whose ability to transactivate transcription is altered by binding to
b-catenin. Each of the tcf/lef transcription factors has a slightly
different structure, and is expressed at different times and by
different cells during normal development. Despite the difference
in structure, all bind and activate the same consensus DNA
sequence, suggesting that the structural differences allow for
specific binding of other proteins with a repressor or enhancer
function (Roose and Clevers, 1999a; Barker et al, 2000). This
could result in the activation of different target genes. Murine data
suggest that this is true for the skin, in which tcf-3 and lef-1 do not
transactivate transcription in the same manner, thought due to the
presence of specific proteins that bind tcf-3 altering its activation
(Gat et al, 1998). 
Although  b-catenin is stabilized in a variety of neoplastic
processes, such as colonic neoplasia, the effects of stabilization
vary between tumour types, as colonic polyps can go on to malig-
nancy, while aggressive fibromatosis only very rarely progresses
to a malignant process. One possibility for the difference in behav-
iour is that stabilized b-catenin binds different transcription
factors, which will activate transcription in a different manner.
Binding to different transcription factors is already demonstrated
between colonic neoplasia (in which b-catenin binds tcf-4) (Morin
et al, 1997) and pilomatricomas (in which b-catenin binds lef-1)
(Chan et al, 1999). 
METHODS 
Patients and case material 
Tumours and normal tissues from 10 patients with sporadic
aggressive fibromatoses were studied. 6 tumours had b-catenin
mutations (substitution of threonine at codon 41), 2 had APC
mutations (one had a frameshift at codon 1567 and the other a
frameshift at codon 1371, both resulting in an early stop codon),
and 2 had no mutations identified in either b-catenin or APC.
Normal fascial tissue from the resection margins were used as
controls. RNA was extracted from 5 colon cancers, and analysed
for transcription factor expression in an identical manner to the
fibromatoses. Control cell lines, were the SW480 (colorectal
cancer cell line, APC mutant producing a high level of b-catenin
protein), HCT116 (colorectal cancer cell line, b-catenin mutant),
CRL1790 (normal colonic epithelium), Jurkat (T-cell lymphoma)
and Molt-4 (acute lymphoblastic leukaemia). 
Tcf transcriptional activation 
Primary cell cultures from the aggressive fibromatosis cases and
normal fibrous tissues were transiently transfected after their first
passage in culture. The SW480 colon cancer cell line was used as
a control. Cells in 35 mm dishes were transiently transfected in
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triplicate with 1000 ng of the luciferase reporter construct
pTOPFLASH or pFOPFLASH. In addition some cell dishes were
also co-transfected with either 1000 ng DN-Tcf-4E; 1000 ng of
DN89  b-catenin (Munemitsu et al, 1996); 1000 ng of the full
length APC gene; or empty vector controls. 3 ml of FuGENE
Transfection Reagent (Boehringer, Mannheim) was used
according to the manufacturer’s protocol, and in all cases, 500 ng
of Rous Sarcoma Virus b-galactosidase DNA was also transfected
as a control for transfection efficiency. Cells were harvested 24–36
hours after the transfection, and luciferase reporter enzyme
activity was measured and normalized to b-2 galactosidase. The
pTOPFLASH reporter construct contains copies of the consensus
binding sequence for tcf transcription factors linked to a luciferase
reporter and the pFOPFLASH reporter construct contains a
mutated binding sequence linked to the reporter as a control
(Morin et al, 1997). In the case of the SW480 cell line and the
aggressive fibromatoses containing APC mutations, the wild-type
APC gene in a CMV vector was transfected. In all of the tumours
a dominant negative tcf, DN tcf- 4E (Tetsu and McCormick, 1999),
was also transfected. DN tcf- 4E binds the tcf consensus sequence,
but prevents transcriptional activation by other transcription
factors. A ratio of the normalized pTOPFLASH/pFOPFLASH
luminescence was calculated for each cell dish. Means and stan-
dard deviations were determined for each cell type and transfection
condition, and compared using the 2 way t-test. 
Transcription factor expression 
Total RNA was isolated using TRIzol reagents (Gibco), and
analysed using RT-PCR and Northern analysis. RT-PCR was
performed using previously described primers and conditions for
expression of Tcf-1, Lef-1, Tcf-3, and Tcf-4 (Zhou et al, 1995;
Korinek et al, 1997). Northern analysis was performed using 32P-
labelled PCR generated probes. GAPDH expression was measured
as a loading control. 
Co-immunoprecipitation with tcf antibodies 
Monoclonal antibodies that recognize either tcf-1, tcf-4, or one
that recognizes both tcf-3 and tcf-4 (tcf-3/4 antibody) were utilized
for co-immunoprecipitation (Barker et al, 1999). Total protein
lysates were isolated using native conditions from an aggressive
fibromatosis primary cell cultures and from the SW480 cell line.
The lysates were then incubated with additional buffer buffer (1%
Triton X-100, 150 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA,
1 mM EGTA pH 8.0, 0.2 mM sodium ortho-vanadate, 0.2 mM
PMSF, 0.5% NP-40), and one of the monoclonal antibodies for
one hour at 4˚C. The antibodies were recovered using Protein A
plus agarose. The immunoprecipitates were subjected to Western
analysis for b-catenin as previously reported (Tejpar et al, 1999). 
RESULTS 
Constitutive b b-catenin mediated tcf-dependent
transcriptional activation in aggressive fibromatosis 
A significant increase in the pTOPFLASH activity was observed
in aggressive fibromatosis cultures over that in primary fibroblast
cell cultures from the same patients (ratio of 12.5 vs 2.5, P < 0.05,
shown in Figure 1). Our previous work showed that APC transfec-
tion into aggressive fibromatosis primary cultures that contained
an APC mutation reduced b-catenin protein level (Li et al, 1998).
Transfection of wild-type APC these cultures also resulted in a
significant decline in pTOPFLASH activity. When a stabilized
form of b-catenin, D-N-89 b-catenin that lacks the amino terminus
phosphorylation sites necessary for protein degradation
(Munemitsu et al, 1996), was transfected into either normal fibro-
blasts, or the aggressive fibromatoses, it resulted in a doubling of
pTOPFLASH/pFOPFLASH ratios (3.1 to 6.8 for the normal
fibroblasts and 12.5 to 20.5 for aggressive fibromatosis cell
cultures). These data illustrate that b-catenin stabilization is
responsible for regulating the tcf-mediated transcriptional activa-
tion in this cell type. The dominant negative tcf, DN-tcf-4E, (He et
al, 1999; Tetsu and McCormick, 1999), was co-transfected into
these cultures, resulting in a significant decline of transcriptional
activation to a level about the same as for normal fibroblasts
(Figure 1). 
Aggressive fibromatosis expresses tcf-3 
Tcf-3 was expressed in all 10 aggressive fibromatoses, as shown in
Figure 2. Tcf-4 was expressed in only 3 of the 10 aggressive fibro-
matoses, while tcf-1 and lef-1 were not expressed. This is in contrast
to colon cancers, which express tcf-4 and tcf-1. Normal fibrous
tissues from the 10 aggressive fibromatosis patients (fascia from the
resection margin) all expressed tcf-3 using RT-PCR, but did not
express any of the other transcription factors (data not shown). 
b b-catenin binds tcf-3 in aggressive fibromatosis 
Western analysis shows b-catenin protein presence in the immuno-
precipite using a tcf-3/4 antibody, but its absence in the immunopre-
cipitate using a tcf-4 antibody (Figure 3). This is in contrast to results
from the SW480 colon cancer cell line extracts, in which tcf-4
immunoprecipitates contained b-catenin protein (Figure 3). 
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Figure 1 Tcf transcriptional activation in primary cell cultures from
aggressive fibromatosis and normal fibrous tissue cells. Ratio of
luminescence is the ratio of pTOPFLASH/pFOPFLASH when normalized for
transfection efficiency. Each bar gives the mean and standard deviation for
the specific cell type tested. For instance the aggressive fibromatosis bar
gives the mean and standard deviation for all of the aggressive fibromatosis
samples, while the AF with APC mutation gives the mean and standard
deviations for the cases of aggressive fibromatosis with an APC mutation. A
higher ratio indicates a higher level of tcf transcriptional activation, with cells
exhibiting no transcriptional activation having a ratio of one. Aggressive
fibromatosis exhibits a high level of tcf transcriptional activation, close to that
of the SW480 colon cancer cell line. Normal fibroblast cultures from the same
patients exhibit a significantly lower level of activation (P < 0.05), and
transfection of the dominant negative tcf into any of the cultures, or
transfection of the full length APC gene into a tumour culture with an APC
mutation, resulted in a level of activation similar to that detected in the normal
fibroblast cultures 100 S Tejpar et al
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DISCUSSION 
We directly demonstrate constitutive transcriptional activation of
the tcf/lef family of transcription factors in aggressive fibro-
matosis. Furthermore, we show that this activation is related to b-
catenin stabilization. In combination with our previous data
(Alman et al, 1997b; Li et al, 1998; Tejpar et al, 1999), this gives
strong evidence that b-catenin mediated tcf-dependent transcrip-
tion plays a key role in the pathogenesis of aggressive fibro-
matosis. 
Tcf-3 was expressed in all of the cases of aggressive fibro-
matosis and in normal fibrous tissue from these same patients.
This is in contrast to colonic neoplasia which our data, as well as
data from other researchers (Korinek et al, 1997; Morin et al,
1997), show express tcf-4; and pilomatricomas, in which lef-1 is
expressed (Chan et al, 1999). Each of the tcf/lef family may regu-
late transcription in a slightly different way (Behrens et al, 1996;
Morin et al, 1997). Xenopus studies suggest that tcf-3 can be
bound selectively by specific repressors such as C-terminal
binding protein (Brannon et al, 1999). Interactions unique to tcf-3
could be responsible for the expression of different b-catenin
mediated target genes in aggressive fibromatosis, partially
explaining the difference in cell behaviour observed between
aggressive fibromatosis and other neoplastic processes exhibiting
b-catenin stabilization. 
We found that tcf-dependent transcriptional activation in
aggressive fibromatosis and normal fibocytes is significantly
upregulated by b-catenin stabilization. This is demonstrated by the
repression of transcriptional activation with transfection of the full
length APC in APC mutant tumours, which leads to a drop in b-
catenin levels; and by the demonstration that overexpression of a
stabilized form of b-catenin enhances activation. Normal fibro-
blasts derived from the same patients with aggressive fibromatosis
do not contain a mutation resulting in b-catenin stabilization, but
do express tcf-3. These fibroblasts do not exhibit tcf-dependent
transcriptional activation, suggesting that b-catenin stabilization is
essential for tcf-3 transcriptional activation. 
Tcf-1 is a negative regulator of b-catenin mediated tcf-dependent
transcriptional activation in colonic epithelial cells. In these cells it
is upregulated by tcf-4 mediated transcription (Roose et al, 1999).
The lack of tcf-1 in aggressive fibromatosis suggests that this nega-
tive regulatory feedback may be lost in aggressive fibromatosis,
contributing to b-catenin mediated transcriptional activation. 
Some of the tcf/lef target genes identified in colon cancer are not
expressed in aggressive fibromatosis. In this study, we found that
the target gene, tcf-1 (Roose et al, 1999) was not expressed in
aggressive fibromatosis. In another study (Poon, et al 2000), we
found that another b-catenin-tcf target gene identified in colonic
neoplasia, PPAR-d (He et al, 1999), was also not upregulated in
aggressive fibromatosis. While there are several potential explana-
tions for the difference in expression of these target genes, one
possibility is that the different profile of tcf/lef family member
expression is responsible for the difference in expression. This
difference in expression of target genes may be one factor respon-
sible for the difference in tumour behaviour between different
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Figure 2 Tcf/lef expression in aggressive fibromatosis. (A) RT-PCR for tcf-3
and tcf-4 from all 10 tumours shows that only 3 express tcf-4. GAPDH
expression is used as a control. (B) Northern analysis for lef-1, tcf-1, 3 and 4,
and GAPDH (as a loading control) from a single membrane containing RNA
loaded from one colonic cancers (lane C) and 5 aggressive fibromatoses
(lanes 1 to 5). Lane P is loaded with RNA from an appropriate cell line for a
positive control. The Jurkat line was used for tcf-1, the Molt-4 for LEF and tcf-
3, and the HCT-116 for tcf-4. The only transcription factor that is expressed
by all of the fibromatoses is tcf-3 
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Figure 3 b-catenin binds tcf-3. Western analysis for b-catenin from tcf
antibody co-immunoprecipitates. Lanes are loaded with immunoprecipitates
using the various antibodies as labelled, with total protein lysate (positive
control), or with an immunoprecipiate obtained without the use of an antibody
(negative control). b-catenin is detected in the tcf3/4 immunoprecipitate in
aggressive fibromatosis, but not in the tcf-4 immunoprecipitate, suggesting 
b-catenin binding to tcf-3 in this tumour. This is in contrast to the
immunoprecipitates from the SW 480 cell line, in which b-catenin is detected
in the immunoprecipitate obtained using the tcf-4 antibody.tcf-3 in aggressive fibromatosis 101
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neoplastic processes exhibiting b-catenin mediated tcf-dependent
transcriptional activation. 
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